RecruitingPhase 2NCT07244406
Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL
Studying Precursor B-cell acute lymphoblastic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
- Principal Investigator
- Xiaojun HuangPeking University People's Hospital
- Intervention
- S1904 CD19 CAR-T(biological)
- Enrollment
- 59 enrolled
- Eligibility
- 3-25 years · All sexes
- Timeline
- 2025 – 2028
Study locations (1)
- Peking University People's Hospital, Beijing, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07244406 on ClinicalTrials.govOther trials for Precursor B-cell acute lymphoblastic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07441291CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCTPeking University People's Hospital
- RECRUITINGNANCT06689917JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ LeukemiaTongji Hospital
- RECRUITINGPHASE2NCT06554626Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALLFirst Affiliated Hospital of Zhejiang University
- RECRUITINGPHASE2NCT06111625Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALLSichuan University
- RECRUITINGPHASE1NCT04318678CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)St. Jude Children's Research Hospital
- RECRUITINGPHASE1, PHASE2NCT03765177CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic MalignanciesOttawa Hospital Research Institute
- ENROLLING BY INVITATIONNCT03226704Leukapheresis for CAR or Adoptive Cell Therapy ManufacturingNational Cancer Institute (NCI)
See all trials for Precursor B-cell acute lymphoblastic leukemia →